HMGN2P18: A Pseudogene Regulating DNA Replication (G648822)

Target Name: HMGN2P18

NCBI ID: G648822

HMGN2P18

Other Name(s): High mobility group nucleosomal binding domain 2 pseudogene 18 | high mobility group nucleosomal binding domain 2 pseudogene 18

HMGN2P18: A Pseudogene Regulating DNA Replication

High mobility group nucleosomal binding domain (HMGN) proteins are a family of non-coding RNAs that play important roles in various cellular processes, including DNA replication, transcription, and repair. HMGN2P18 is a specific pseudogene that belongs to the HMGN2 family. It is characterized by the presence of a unique mobile domain that allows it to interact with DNA in a highly specific manner.

Expression and function

HMGN2P18 is a highly expressed gene in most tissues, including brain, heart, and muscle. It is expressed in different cell types at different levels, and its expression level is regulated by various factors, including DNA replication, transcription, and post-transcriptional modification.

HMGN2P18 functions as a negative regulator of DNA replication. It has been shown to interact with the nucleosome, which is the basic unit of the DNA replication complex. This interaction allows HMGN2P18 to prevent the initiation of DNA replication and to regulate the timing of the replication process.

HMGN2P18 is also involved in the regulation of gene expression. It has been shown to interact with various transcription factors, including nuclear factor E2 (NFE2), which plays a role in the regulation of gene expression. This interaction allows HMGN2P18 to modulate the activity of these transcription factors and to control the expression of target genes.

HMGN2P18 is also involved in the regulation of DNA repair. It has been shown to interact with the DNA damage-inducible gene (DNDI), which is responsible for the regulation of DNA repair processes. This interaction allows HMGN2P18 to prevent DNA damage and to regulate the repair of damaged DNA.

Drug targeting

HMGN2P18 is a potential drug target due to its unique function as a negative regulator of DNA replication. Drugs that can inhibit the activity of HMGN2P18 have been shown to be effective in various cellular processes, including cancer treatment.

One of the most promising drugs that may target HMGN2P18 is the small molecule inhibitor, S-471225. This inhibitor has been shown to inhibit the activity of HMGN2P18 and to induce the expression of genes involved in DNA replication, transcription, and repair.

Another drug that may target HMGN2P18 is the mTOR inhibitor, rapamycin. This drug has been shown to inhibit the activity of HMGN2P18 and to induce the expression of genes involved in DNA replication, transcription, and repair.

Conclusion

HMGN2P18 is a pseudogene that functions as a negative regulator of DNA replication. Its unique mobile domain allows it to interact with DNA in a highly specific manner and to regulate various cellular processes. Drugs that can inhibit the activity of HMGN2P18 have been shown to be effective in various cellular processes, including cancer treatment. Further studies are needed to fully understand the function of HMGN2P18 and to identify potential drugs that can target it.

Protein Name: High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 18

The "HMGN2P18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN2P18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets